.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

INOMAX Drug Profile

« Back to Dashboard
Inomax is a drug marketed by Mallinckrodt Hosp and is included in one NDA. It is available from one supplier. There are sixteen patents protecting this drug and one Paragraph IV challenge.

This drug has eleven patent family members in eight countries.

The generic ingredient in INOMAX is nitric oxide. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nitric oxide profile page.

Summary for Tradename: INOMAX

Patents:16
Applicants:1
NDAs:1
Suppliers / Packagers: see list1

Pharmacology for Tradename: INOMAX

Drug ClassVasodilator
Physiological EffectVasodilation

Clinical Trials for: INOMAX

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mallinckrodt Hosp
INOMAX
nitric oxide
GAS;INHALATION020845-003Dec 23, 1999RXYes5,752,504*PED<disabled>Y<disabled>
Mallinckrodt Hosp
INOMAX
nitric oxide
GAS;INHALATION020845-003Dec 23, 1999RXYes5,732,693*PED<disabled>Y<disabled>
Mallinckrodt Hosp
INOMAX
nitric oxide
GAS;INHALATION020845-002Dec 23, 1999DISCNNo8,573,210*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: INOMAX

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mallinckrodt Hosp
INOMAX
nitric oxide
GAS;INHALATION020845-002Dec 23, 19995,558,083*PED<disabled>
Mallinckrodt Hosp
INOMAX
nitric oxide
GAS;INHALATION020845-002Dec 23, 19995,485,827*PED<disabled>
Mallinckrodt Hosp
INOMAX
nitric oxide
GAS;INHALATION020845-003Dec 23, 19995,873,359*PED<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: INOMAX

Drugname Dosage Strength RLD Submissiondate
nitric oxidefor Inhalation100 ppm and 800 ppmINOmax5/20/2014

International Patent Family for Tradename: INOMAX

Country Document Number Estimated Expiration
Canada2779766<disabled in preview>
World Intellectual Property Organization (WIPO)2012094008<disabled in preview>
Australia2011328891<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: INOMAX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
02C/003Belgium<disabled>PRODUCT NAME: NITRIC OXIDE; REGISTRATION NO/DATE: EU/1/01/194/001 20010801
C/GB08/019United Kingdom<disabled>PRODUCT NAME: NITRIC OXIDE (NO); REGISTERED: UK EU/1/01/194/001 20010801
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc